Ken Griffin Oragenics Inc Transaction History

Citadel Advisors LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$0.11 - $15.59 $9,536 - $1.35 Million	86,698 New	86,698 $9,000
Q1 2022 May 16, 2022	SELL	$0.33 - $0.56 $17,943 - $30,450	-54,375 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$0.43 - $0.69 $34,651 - $55,603	-80,585 Reduced 59.71%	54,375 $24,000
Q3 2021 Nov 15, 2021	SELL	$0.58 - $0.84 $136,625 - $197,871	-235,561 Reduced 63.58%	134,960 $86,000
Q1 2021 May 17, 2021	BUY	$0.52 - $1.52 $83,947 - $245,384	161,437 Added 77.21%	370,521 $336,000
Q4 2020 Feb 16, 2021	BUY	$0.39 - $0.6 $67,562 - $103,942	173,237 Added 483.27%	209,084 $94,000
Q3 2020 Nov 16, 2020	BUY	$0.56 - $1.49 $3,236 - $8,612	5,780 Added 19.22%	35,847 $21,000
Q3 2018 Nov 13, 2018	BUY	$0.38 - $1.42 $11,425 - $42,695	30,067 New	30,067 $0

Ticker OGEN
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 116,395,000
Market Cap $41.9M
Description
Oragenics, Inc. develops antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus; and Terra CoV-2, an intramuscular vaccine candidate that provides immuni...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.